Faricimab-svoa (Vabysmo™)

Vabysmo (faricimab‑svoa) is covered only for FDA‑approved indications—neovascular (wet) AMD and diabetic macular edema—with approvals up to 12 months and dosing limited to 6 mg intravitreal: for nAMD, no more frequently than every 4 weeks for four doses then no more frequently than every 8 weeks; for DME, no more frequently than every 4 weeks. Coverage requires documentation of the FDA‑approved diagnosis, adherence to the specified dosing schedule, and administration by or under the supervision of an ophthalmologist.

"Neovascular (wet) age-related macular degeneration (nAMD)"

Sign up to see full coverage criteria, indications, and limitations.